Revolutionizing the mRNA Technology
Your DNA/RNA expert in the field of modification for almost two decades
Since 2022, baseclick is provider in custom synthesis of mRNA for research and pre-clinical applications. Our team of experts transforms your mRNA design ranging from research tool to mRNA product development.
baseclick enables life science researchers to create better solutions in diagnostics, therapeutics and vaccines development through a proprietary click chemistry.
Click technology holds the promise to revolutionize the mRNA Technology. One example is – ethynyl uridine (EU) – which is a derivate used to replace uridine in mRNA-based therapies and vaccines. EU-modified mRNA exhibits prolonged expression and confers similar low immunogenicity compared to the other uridine derivates such a pseudo-uridine and methyl-pseudo-uridine. Discoveries like these encourage us to demonstrate the advantages of our technology to pharmaceutical companies.
Our mission
We are on a mission to change the way therapeutics and vaccines are developed and manufactured. By focusing on targeted delivery agents instead of lipid nanoparticles (LNPs), we leverage the significant benefits of our modified nucleic acid building blocks to pioneer novel therapies and compounds. Our goal is to develop treatments for disease patients and improve the lives of millions of people around the world.
mRNA Configurator
Click technology holds the promise to revolutionize the mRNA Technology in drug development for cancer treatment, vaccine discovery and enables tailored manufactured mRNA with superior quality.
baseclick supplies diverse types of mRNA
– High quality products and services at competitive prices
– Custom tailored support to meet specific applications
– Wide variety of modification
– Affordable custom synthesis up to 10 mg scales of mRNA
5-Ethynyl uridine (5-EU)
An uridine derivate for replacement of uridine in mRNA-based therapies and vaccines. Modified mRNA shows prolonged expression and confers similar low immunogenicity compared to the other uridine derivates such a pseudo-uridine and methyl-pseudo-uridine.
Targeted delivery agent – Tri-GalNAc-DBCO
Tri-GalNAc-DBCO enables the possibility to click label an azide modified nucleic acid molecule with an Tri-GalNAc by strain-promoted Alkyne-Azide cycloaddition (SPAAC). The Tri-GalNAc structure is recognized by the cellular surface protein asialoglycoprotein receptor (ASGPR) and can be used for targeted delivery of biomolecules such as siRNA, ASOs, mRNA etc. into ASGPR expressing cells for example to liver cells.
Targeted delivery agent – Azido-PEG4-Trimannose
Azido-PEG4-Trimannose enables the possibility to click label an Alkyne or DBCO modified nucleic acids with an 3,6-di-O-(α-D-mannopyranosyl)-α-D-mannopyranoside moity by CuAAC. The Trimannose structure is recognized by the mannose receptor and leads to transportation into the cell by internalized receptor mediated endocytosis. Therefore, this molecule offers a possibility for target delivery of biomolecules to the cell.
Targeted delivery agent – Tri-β-GalNAc-PEG3-Azide
Tri-GalNAc-DBCO enables the possibility to click label an azide modified nucleic acid molecule with an Tri-GalNAc by strain-promoted Alkyne-Azide cycloaddition (SPAAC). The Tri-GalNAc structure is recognized by the cellular surface protein asialoglycoprotein receptor (ASGPR) and can be used for targeted delivery of biomolecules such as siRNA, ASOs, mRNA etc. into ASGPR expressing cells for example to liver cells.
Custom oligonucleotide
You are searching for individual oligonucleotides? baseclick is offering special DNAs, RNAs and even LNAs for your specific application. We are glad to provide you with a wide range of special modifications.
5-Ethynyluridine: A Bio-orthogonal Uridine Variant for mRNA-Based Therapies and Vaccines
The identification of pseudo- and N1-methylpseudo-uridine (Ψ and mΨ, respectively) as immunosilent uridine analogues has propelled the development of mRNA-based vaccines and therapeutics. Here, we have characterised another uridine analogue, 5-ethynyluridine (EU), which has an ethynyl moiety. We show that this uridine analogue does not cause immune activation in human macrophages, as it does not induce interleukin-6 secretion or expression of the inflammatory and antiviral genes MX1, PKR, and TAP2. Moreover, EU allows for prolonged expression, as shown with mRNA coding for yellow fluorescent protein (YFP). Side-by-side comparisons of EU with unmodified, Ψ, and mΨ revealed that EU-modified mRNA is expressed at lower levels, but confers similar stability and low immunogenicity to the other uridine analogues. Furthermore, structure analysis of modified mRNAs suggests that the observed phenotype is largely independent of RNA folding. Thus, EU is a potential candidate for RNA-based vaccines and therapeutics.
Trimannose-coupled antimiR-21 for macrophage-targeted inhalation treatment of acute inflammatory lung damage
Recent studies of severe acute inflammatory lung disease including COVID-19 identify macrophages to drive pulmonary hyperinflammation and long-term damage such as fibrosis. Here, we report on the development of a first-in-class, carbohydrate-coupled inhibitor of microRNA-21 (RCS-21), as a therapeutic means against pulmonary hyperinflammation and fibrosis. MicroRNA-21 is among the strongest upregulated microRNAs in human COVID-19 and in mice with acute inflammatory lung damage, and it is the strongest expressed microRNA in pulmonary macrophages. Chemical linkage of a microRNA-21 inhibitor to trimannose achieves rapid and specific delivery to macrophages upon inhalation in mice. RCS-21 reverses pathological activation of macrophages and prevents pulmonary dysfunction and fibrosis after acute lung damage in mice. In human lung tissue infected with SARS-CoV-2 ex vivo, RCS-21 effectively prevents the exaggerated inflammatory response. Our data imply trimannose-coupling for effective and selective delivery of inhaled oligonucleotides to pulmonary macrophages and report on a first mannose-coupled candidate therapeutic for COVID-19.
